XML 20 R43.htm IDEA: XBRL DOCUMENT v3.20.1
Significant Accounting Policies - Additional Information (Detail)
12 Months Ended
Jul. 02, 2018
USD ($)
Mar. 28, 2018
Jul. 02, 2016
USD ($)
Dec. 31, 2019
USD ($)
Lease
Jan. 01, 2019
USD ($)
Dec. 31, 2018
USD ($)
Schedule Of Significant Accounting Policies [Line Items]            
Accumulated other comprehensive income to foreign currency translation       $ 840,000   $ 839,000
Interest-bearing cash equivalent       20,000,000    
Marketable securities       0   0
Allowance for doubtful accounts receivable       0    
Operating lease liability       3,379,000    
Operating lease right-of-use assets       $ 3,078,000   $ 0
DEXYCU [Member] | Icon Bioscience Inc [Member]            
Schedule Of Significant Accounting Policies [Line Items]            
Finite-lived intangible asset, useful life   13 years   11 years 3 months    
Accounting Standards Update 2018-11            
Schedule Of Significant Accounting Policies [Line Items]            
Operating lease liability         $ 3,700,000  
Number of real estate operating lease arrangements | Lease       3    
Operating lease right-of-use assets         $ 3,500,000  
Accounting Standards Update 606 [Member]            
Schedule Of Significant Accounting Policies [Line Items]            
Decrease (Increase) in accumulated deficit resulting from changes in accounting principles $ 218,000          
Accounting Standards Update 2016-09 [Member]            
Schedule Of Significant Accounting Policies [Line Items]            
Decrease (Increase) in accumulated deficit resulting from changes in accounting principles     $ (122,000)      
Minimum [Member]            
Schedule Of Significant Accounting Policies [Line Items]            
Accounts receivable standard payment terms       120 days    
Estimated useful lives of assets       3 years    
Maximum [Member]            
Schedule Of Significant Accounting Policies [Line Items]            
Accounts receivable standard payment terms       154 days    
Estimated useful lives of assets       5 years    
3 PL [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]            
Schedule Of Significant Accounting Policies [Line Items]            
Percentage of concentration risk       37.00%    
3 PL [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member]            
Schedule Of Significant Accounting Policies [Line Items]            
Percentage of concentration risk       56.00%    
ASD Specialty Healthcare LLC [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]            
Schedule Of Significant Accounting Policies [Line Items]            
Percentage of concentration risk       34.00%    
ASD Specialty Healthcare LLC [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member]            
Schedule Of Significant Accounting Policies [Line Items]            
Percentage of concentration risk       15.00%    
FFF Enterprises, Inc. [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]            
Schedule Of Significant Accounting Policies [Line Items]            
Percentage of concentration risk       15.00%    
McKesson Specialty Care Distribution LLC [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]            
Schedule Of Significant Accounting Policies [Line Items]            
Percentage of concentration risk       12.00%    
Alimera Sciences [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member]            
Schedule Of Significant Accounting Policies [Line Items]            
Percentage of concentration risk       10.00%